These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 6319859

  • 1. Physical separation of the agonist and antagonist forms of a mu opiate receptor?
    Jauzac P, Puget A, Meunier JC.
    Life Sci; 1983; 33 Suppl 1():195-8. PubMed ID: 6319859
    [Abstract] [Full Text] [Related]

  • 2. Differential regulation of two molecular forms of a mu-opioid receptor type by sodium ions, manganese ions and by guanyl-5'-yl imidodiphosphate.
    Jauzac P, Frances B, Puget A, Moisand C, Meunier JC.
    J Recept Res; 1986; 6(1):1-25. PubMed ID: 3012080
    [Abstract] [Full Text] [Related]

  • 3. Apparent precoupling of kappa- but not mu-opioid receptors with a G protein in the absence of agonist.
    Frances B, Puget A, Moisand C, Meunier JC.
    Eur J Pharmacol; 1990 Jul 31; 189(1):1-9. PubMed ID: 2171960
    [Abstract] [Full Text] [Related]

  • 4. Distinct molecular forms of opiate binding in the frog brain.
    Puget A, Jauzac P, Meunier JC.
    Life Sci; 1983 Jul 31; 33 Suppl 1():199-202. PubMed ID: 6319860
    [Abstract] [Full Text] [Related]

  • 5. 5'-Guanylylimidodiphosphate decreases affinity for agonists and apparent molecular size of a frog brain opioid receptor in digitonin solution.
    Mollereau C, Pascaud A, Baillat G, Mazarguil H, Puget A, Meunier JC.
    J Biol Chem; 1988 Dec 05; 263(34):18003-8. PubMed ID: 2848020
    [Abstract] [Full Text] [Related]

  • 6. Divalent cations: do they stabilize the agonist (12S) form of the mu opioid receptor?
    Jauzac P, Frances B, Puget A, Meunier JC.
    Neuropeptides; 1984 Dec 05; 5(1-3):125-8. PubMed ID: 6099479
    [Abstract] [Full Text] [Related]

  • 7. Solubilization of two molecular forms of the frog brain opioid receptor.
    Puget A, Frances B, Jauzac P, Meunier JC.
    Neuropeptides; 1984 Dec 05; 5(1-3):129-32. PubMed ID: 6099480
    [Abstract] [Full Text] [Related]

  • 8. Multiple opiate binding sites in the central nervous system of the rabbit. Large predominance of a mu subtype in the cerebellum and characterization of a kappa subtype in the thalamus.
    Meunier JC, Kouakou Y, Puget A, Moisand C.
    Mol Pharmacol; 1983 Jul 05; 24(1):23-9. PubMed ID: 6306437
    [Abstract] [Full Text] [Related]

  • 9. [Opiate receptor(s) of the frog brain: soluble-phase separation of the macromolecular complexes of an agonist and an antagonist].
    Puget A, Meunier JC.
    C R Seances Acad Sci III; 1983 Jul 05; 296(10):475-8. PubMed ID: 6307492
    [Abstract] [Full Text] [Related]

  • 10. Na+ ions and Gpp(NH)p selectively inhibit agonist interactions at mu- and kappa-opioid receptor sites in rabbit and guinea-pig cerebellum membranes.
    Frances B, Moisand C, Meunier JC.
    Eur J Pharmacol; 1985 Nov 05; 117(2):223-32. PubMed ID: 2866971
    [Abstract] [Full Text] [Related]

  • 11. Characterization of kappa opiate receptors in rat spinal cord-dorsal root ganglion cocultures and their regulation by chronic opiate treatment.
    Attali B, Vogel Z.
    Brain Res; 1990 May 28; 517(1-2):182-8. PubMed ID: 2165432
    [Abstract] [Full Text] [Related]

  • 12. Solubilization and preliminary characterization of mu and kappa opiate receptor subtypes from rat brain.
    Chow T, Zukin RS.
    Mol Pharmacol; 1983 Sep 28; 24(2):203-12. PubMed ID: 6310362
    [Abstract] [Full Text] [Related]

  • 13. The kappa-opioid receptor from human placenta: hydrodynamic characteristics and evidence for its association with a G protein.
    Porthé G, Francés B, Verrier B, Cros J, Meunier JC.
    Life Sci; 1988 Sep 28; 43(6):559-67. PubMed ID: 2841553
    [Abstract] [Full Text] [Related]

  • 14. Buprenorphine: differential interaction with opiate receptor subtypes in vivo.
    Sadée W, Rosenbaum JS, Herz A.
    J Pharmacol Exp Ther; 1982 Oct 28; 223(1):157-62. PubMed ID: 6288917
    [Abstract] [Full Text] [Related]

  • 15. Guanine nucleotides inhibit binding of agonists and antagonists to soluble opiate receptors.
    Koski G, Simonds WF, Klee WA.
    J Biol Chem; 1981 Feb 25; 256(4):1536-8. PubMed ID: 6257676
    [Abstract] [Full Text] [Related]

  • 16. In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method.
    Richards ML, Sadée W.
    Eur J Pharmacol; 1985 Aug 27; 114(3):343-53. PubMed ID: 2998812
    [Abstract] [Full Text] [Related]

  • 17. [3H]-etorphine and [3H]-diprenorphine receptor binding in vitro and in vivo: differential effect of Na+ and guanylyl imidodiphosphate.
    Kurowski M, Rosenbaum JS, Perry DC, Sadée W.
    Brain Res; 1982 Oct 14; 249(2):345-52. PubMed ID: 6291717
    [No Abstract] [Full Text] [Related]

  • 18. Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic etorphine treatment.
    Tao PL, Law PY, Loh HH.
    J Pharmacol Exp Ther; 1987 Mar 14; 240(3):809-16. PubMed ID: 3031275
    [Abstract] [Full Text] [Related]

  • 19. Etorphine binds to multiple opiate receptors of the caudate nucleus with equal affinity but with different kinetics.
    Tolkovsky AM.
    Mol Pharmacol; 1982 Nov 14; 22(3):648-56. PubMed ID: 6296657
    [Abstract] [Full Text] [Related]

  • 20. Opiate receptor thermodynamics: agonist and antagonist binding.
    Hitzemann R, Murphy M, Curell J.
    Eur J Pharmacol; 1985 Jan 22; 108(2):171-7. PubMed ID: 2984022
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.